Compare Trade Desk Inc (TTD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

The Trade Desk (TTD) trades at $12.18, down 68% year-to-date amid slowing revenue growth and increased competition. Technical indicators show bearish momentum with mixed earnings performance, beating estimates in Q2 but missing in Q1. The company maintains strong profitability margins (76.9% gross margin) but faces headwinds from Amazon and other tech giants expanding into ad-tech. Recent workforce reductions and downward revenue guidance reflect operational challenges.

Despite current pressures, TTD maintains leadership in programmatic advertising with solid cash flow generation. Analyst consensus suggests 20% upside to the $14.68 price target, though competitive threats and slowing growth present significant risks. The stock's valuation appears reasonable with P/E of 0.14 and P/S of 0.02, but investors should weigh the company's ability to defend its market position against larger competitors.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.